Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Cost Cutting on the Way

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Dec 03, 2022 5:07pm

172 Views

Post# 35148885

RE:Cost Cutting on the Way

Is it possible they have a protocol amendment within days or weeks and continue as they have been, rather than slash and burn and rebuild? If it's month's out, then yes, by all means, slash and burn.

SPCEO1 wrote: THTX now needs to cut costs and do so quickly. How they do that, how quickly they do that and, most importantly, how they commuicate that to investors, will likely play a big role in how big of a bounce the stock has.

Let's say THTX achieved $80 million in sales in fiscal 2022 just completed. If the reenrgized sales force keeps the momentum going, maybe sales grow in the 15-18% range in 2023 to $92 to $95 million. That would be a really nice outcome except for the bloated cost situation they now face. Costs in the recently reported third quarter annualize to $120 million and operating cash flow was likely negative $14-$15 million in fiscal 2022. So, they need to find that much in savings ASAP to get to cash flow breakeven at a minimum. To get to breakeven on an earnings basis they need to cut costs by 20-25%.

It is a tall order and it is an ugly turn of events for so many employees at TH. But it has to be done.

If the revised approach to cancer yields better results, then can put back in place what they have to dismantle now as they will be able to raise money via a better priced equity offering.

Also, we better hope there is no new covid lockdowns this winter that would negatively impact sales as that would threaten the $75 million in trailing 12 month sales criteria for the second tranche of the loan meant to repay most of the remaining convertible still outstanding.

It would also be nice to get sales up to at least the $90 million level by the end of 2023 so the third tranche can be taken down which extends the interest only portion of the loan from 2024 to 2025 and the term of the loan to 6 years from 5. They also need to get an approval for the FB by the end of 2023 to qualify for the third tranche before the incentives on the interest only and term length expire.

But first, take a hatchet to costs.